Drug Type Biological products |
Synonyms PHI-501 |
Target |
Action antagonists, inhibitors |
Mechanism DDR1 antagonists(Discoidin domain receptor 1 antagonists), NRAS inhibitors(GTPase NRas inhibitors), Raf kinase inhibitors(RAF serine/threonine protein kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Application |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colonic Cancer | IND Application | South Korea | 30 Jul 2024 | |
Melanoma | IND Application | South Korea | 30 Jul 2024 | |
Triple Negative Breast Cancer | IND Application | South Korea | 30 Jul 2024 | |
Lung Cancer | Preclinical | South Korea | 29 Apr 2025 | |
Acute Myeloid Leukemia | Preclinical | South Korea | 03 Dec 2021 |